SAN DIEGO, Dec. 22, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT ®-DCP study evaluating the efficacy, safety, and tolerability of ...
(BPT) – This article was sponsored and developed by Neurocrine Biosciences, Inc. Cerebral palsy (CP) is a neurodevelopmental disorder affecting movement and posture that begins in early childhood ...
The study did not meet its primary endpoint of chorea improvement or key secondary endpoints at the time of analysis. Topline data were announced from a phase 3 trial evaluating valbenazine in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results